Phase II Trial of Crenolanib and 7+3 Chemotherapy in Newly Diagnosed FLT3-Mutated AML: Long-term Results

Source: 2022 ASCO Annual Meeting*
Download Slideset
June 3-7, 2022; Chicago, Illinois
Patients with newly diagnosed FLT3-mutated AML demonstrated high overall response rates and high 3-year EFS and OS rates with crenolanib plus 7+3 after a median follow-up of 45 months.
Format: Microsoft PowerPoint (.ppt)
File Size: 138 KB
Released: June 17, 2022

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
AstraZeneca
Gilead Sciences, Inc.
Merck Sharp & Dohme Corp.
Novartis Pharmaceuticals Corporation
Seagen

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings